0A4X.L

DMK Pharmaceuticals Corporation, an innovative neuro-biotechnology firm in the clinical development phase, concentrates on developing and commercializing medical solutions for various therapeutic areas, including allergies, opioid overdose, respiratory conditions, and inflammatory diseases. Its primary investigational drug, DPI-125, is currently in clinical trials for the treatment of opioid use disorder. The company's product offerings include SYMJEPI, an epinephrine injection intended for the urgent management of acute allergic reactions caused by insect stings/bites, food, medications, diagnostic substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis. Additionally, they provide ZIMHI, a naloxone injection specifically formulated for reversing opioid overdoses. Having previously operated as Adamis Pharmaceuticals Corporation, the company officially rebranded to DMK Pharmaceuticals Corporation in September 2023. Its operational base is located in San Diego, California. However, on February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliated entities, filed a voluntary petition for Chapter 11 reorganization with the U.S. Bankruptcy Court for the District of Delaware.